061111 HyperPP - PPA Presentation

34
7/23/2019 061111 HyperPP - PPA Presentation http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 1/34 Hyperkalemic Periodic Paralysis Preliminary Survey Results & Management Guidelines  Grace Charles, Chengjie Zheng, Jacob Levitt, MD The Mount Sinai School of Medicine, NY

Transcript of 061111 HyperPP - PPA Presentation

Page 1: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 1/34

Hyperkalemic Periodic Paralysis

Preliminary Survey Results

&

ManagementGuidelines 

Grace Charles, Chengjie Zheng,

Jacob Levitt, MD

The Mount Sinai School of Medicine, NY

Page 2: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 2/34

Contents

• History of HyperPP

• Intro to HyperPP

• Signs & Symptoms

Our study: addressesthese gray areas

 –  General Information

 –  Diagnosis & Symptoms

 –  Treatment and

Management

 –  Special Situations andConclusion

• Prevention

• Management

• Ideas

Special Situations• Tips from Fellow

HyperPPers

Page 3: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 3/34

History of HyperPP

• 1st family identified 60 years ago –  Episodes: frequent short attacks of paralysis

 –  Triggers: rest after exercise, stress, and certain foods

 –  Genetics: autosomal dominant, complete penetrance

 –  Reference: Tyler et al, 1951

• 2nd family 5 years later –  K+ levels were high in some members

 –  K+ administration precipitated attacks

 –  Reference: Gamstorp, 1956

• These two reports clearly distinguished hyperPP from the more

common hypokalemic periodic paralysis

Page 4: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 4/34

Intro to HyperPP

• What: episodes of muscleweakness –  Induced by increased K+ levels

 –  +/- paramyotonia congenita

(PMC)• Why: autosomal dominant

hyper = high

kalemia = blood potassium level periodic = occurring at intervals

 paralysis = loss of ability to move

Page 5: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 5/34

Intro to HyperPP

• How: mutated skeletal muscle sodium channel

• Who: onset in infancy or early childhood; prevalence1:200,000; M = F

• When/where: usually triggered by cold exposure, restafter exercise, fasting, stress, ingestion of potassium,e.g. bananas or orange juice, or anesthesia

Page 6: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 6/34

Signs & Symptoms

• Attacks of weakness

 –  Focal, affecting one limb, OR generalized flaccid

paralysis

 –  Spares consciousness, cranial muscles, respiration

 –  +/- muscle pain with attacks

 –  +/- arrhythmias from high K+

Page 7: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 7/34

Signs & Symptoms

• +/- Myotonia between attacks

 –  Myotonia: delayed muscle relaxation after

contraction (i.e., stiffness/rigidity)

• Adolescence/early adulthood:

 –  Attacks most frequent

• Between ages 30 and 60:

 –  Attacks decrease in frequency

 –  Permanent muscle weakness

Page 8: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 8/34

Our Survey

• Recruitment through PPA, PPA medical advisors

• 4 main categories of questions

 –  General Information

 –  Diagnosis & Symptoms –  Treatment and Management

 –  Special Situations and Conclusion

• 72 responses 43 documented mutations, fromUSA, Canada, Germany, India, Singapore

 –  Some participants chose not to answer certainquestions so not all questions had 43 responses

Page 9: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 9/34

Respondent Characteristics

Diagnosis HyperKPP (22)HyperKPP with paramyotonia congenita (21)

Age 0-20 (3) 21-30 (6) 31-40 (8) 41-50 (11) 51-60 (5) 61+ (10)

Sex Male (21) Female

(20)

Blank (2)

Family

History

Child (25)

Maternal grandparent (21)

Aunt/Uncle (16)

Sibling (14)

Parent (9)Grandchild (9)

Paternal grandparent (4)

 All mutation-positive respondents had family history of

HyperKPP

Page 10: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 10/34

Comorbidities:(? Due to no exercise & high carbs?) 

• High triglycerides/cholesterol (7)

• Thyroid problems (7)

• High blood pressure (4)

• Migraines (4)

• CAD (3)

• Arrhythmias (3)

• DM2 (3)

• Kidney problems (2)

Page 11: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 11/34

Diagnosis

Age at first

attack0-1 yrs (13) 2-10 yrs (18) 11-20 yrs (5)

Time to

diagnosis

(~50% > 7 yrs)

< 1 yr (5) 1-5 yrs (2) 7-10 yrs (5) >11 yrs (15)

Specialists

• 29/43 (~70%) saw 2-3 physicians before diagnosis 

• Neurologists were felt to be most valuable (rated

4.5/5) 

Misdiagnoses(~40%)

Malingering/Faking it

(8)

Conversiondisorder

(4)

HypoKPP(3)

Depression(1)

Page 12: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 12/34

Attack Characteristics

Warning

period

<60 min (30)

1-5h (3)

Type of

attacks

Weakness + stiffness (27)

Primarily weakness (26)

Primarily stiffness (17)

Body parts Partial body (19)

Total body (11)

Only muscles used prior to attack (9)

Severity ofattacks/

function

Mild (15)Moderate (21)

Severe (5)

Page 13: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 13/34

Attack Characteristics, continued

Frequency <1-3 X/month (15)

1-6 X/week (13)

1-4 X/day (9)

Duration <1 hour (12)1-4 hours (7)

20+ hours (8)

Time of day Morning (20)

Upon waking (14)During sleep (18)

Afternoon (9) Evening (6)

Night (10)

Page 14: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 14/34

Areas Affected by Attacks

0

5

10

15

20

25

30

35

40

   s   p   e   a    k   i   n   g

   m   u   s   c   u    l   a   t   u   r   e

    b   r   e   a   t    h   i   n   g

   m   u   s   c   u    l   a   t   u   r   e

    f   a   c   e

   e   y   e    l   i    d   s

   n   e   c    k

   a   r   m   s

    h   a   n    d   s

    h   i   p   s

   t    h   i   g    h

   c   a    l    f

    f   e   e   t

   N   u   m    b   e   r   o    f   R   e

   s   p   o   n    d   e   n   t   s

Page 15: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 15/34

Associated Symptoms

0

5

10

15

20

25

   N   u   m    b   n   e   s   s    /

   t   i   n   g    l   i   n   g

   S   w   e   a   t   i   n   g

   P   a    l   p   i   t   a   t   i   o   n   s

   S    h   o   r   t   n   e   s   s   o    f

    b   r   e   a   t    h    /   D   i    f    f   i   c   u    l   t   y

    b   r   e   a   t    h   i   n   g

   L   o   s   s   o    f

    b    l   a    d    d   e   r   c   o   n   t   r   o    l

   L   o   s   s   o    f

    b   o   w   e    l   c   o   n   t   r   o    l

   N   u   m    b   e   r   o    f   r   e   s   p   o   n    d   e   n   t   s

Page 16: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 16/34

Symptoms Surrounding Attacks 

• Symptoms After Attacks –  Muscle Pain (56%) (N=24)

 –  Clumsiness (35%) (N=15)

 –  Extreme fatigue (30%) (N=13)

 –  Irritability (30%) (N=13)

 –  Mental dullness (14%) (N=6)

• Mood Around Attacks (~30-40%) –  Irritable (17) –  Lethargic (15)

 –  Depressed (12)

Page 17: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 17/34

Triggers for Attacks

0

5

1015

20

25

30

35

   R   e   s   t   a    f   t   e   r   e   x

   e   r   c   i   s   e

   H

   u   n   g   e   r

   S   p   e   c   i    f   i   c    f   o   o    d   s    /    b   e   v   e

   r   a   g   e   s

   A    l   c   o    h   o    l

   C   o    l    d

   C    h   a   n   g   e   i   n    h   u   m   i    d   i   t   y

   S   i   c

    k   n   e   s   s

   E   x   t   r   a

   s    l   e   e   p

   S   t   r   e   s   s    /    f   a   t   i   g   u   e

   M   e    d   i   c   a   t   i   o   n   s

   M   e   n   s   t   r   u   a    l   c   y   c    l   e

   P   r   e   g

   n   a   n   c   y

   C    h   a   n   g   e   s   i   n   a   c   t   i   v   i   t   y    l   e   v   e    l

   P   o   t   a   s   s   i   u   m    i

   n    f   o   o    d

   P   o   t   a   s   s   i   u   m    s

   u   p   p    l   e   m   e   n   t   s

   N   u   m    b   e   r   o

    f   r   e   s   p   o   n    d   e   n   t   s

Page 18: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 18/34

Disease Effects

WeightWeight gain (16)

(37%)No effect (25)

Progressive

myopathy

Yes (13)

(30%) No (17) Unsure (12)

Hypokalemic

weaknessNo (20)

Yes (7)

(16%)

Effects on

aspects of life

Mental health (14)

Physical health

(21)

Family life (20)

Relationships (11)

Work (27)

School (19)

M di ti M t

Page 19: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 19/34

Medication ManagementMedications

for acute

attacks

None (5)

Diuretics* (5)

Magnesium (4)

Beta-2 agonists* (4)

Antiarrhythmics* (3)

Anticonvulsants (2)

Potassium (2)

Glucose tablets (2)

Ability to

abort

attacks

All of the time (0)

Most of the time

(12)

Some of the time

(12)

Occasionally (5)

Never (9)

Chronicmedications Diamox (12)HCTZ (10)

Salbutamol (6)

Mexitil (5)Daranide (2)

Glucose tablets (1)

Lasix (1)IV Ca gluconate (0)

Level of

control

Needs

improvement (15)

Mostly controlled

(15)

Optimal (2)

Time to

regimen

<2 years (3) 2-4 years (2) 9-20 years (4)

Rx to avoid (Open-Ended ): Potassium, corticosteroids, antibiotics, statins,

diuretics

*Diuretics: HCTZ, Diamox, Daranide, torsemide, Lasix*Beta-2 agonists: salbutamol, fenoterol

*Antiarrhythmics: propafenone, flecainide, Mexitil*Anticonvulsants: Lamictal, Topamax, Trileptil, carbamazepine

Page 20: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 20/34

Dietary ManagementMeal frequency 1 meal per day (0)

2 meals per day (2)

3 meals per day (9)

4 meals per day (6)

5 meals per day (2)

6 meals per day (1)

Frequency of

carbohydrate-

rich snacks

Never (1)

Every 2 hours (1)

Every 2.5-3 hours (4)Food quantity Small (4)

Medium (18)

Large (4)

Faster response

with liquid vs.

solid sweets

Liquid sweets (9)

Solid sweets (3)

No difference/ have not noticed (17)

Foods to avoid Bananas (15)

Alcohol (10)

Diet soda (6)

Dried figs (6)

Tomato/vegetable juices (5)

Apricots (5)

Page 21: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 21/34

Helpful Foods

0

2

4

6

8

10

12

14

16

   N   u   m    b   e   r   o    f   r   e   s   p   o   n    d   e   n   t   s

Page 22: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 22/34

Other Management

Acute management Keeping warm (17)Sugary food (12)

Gentle exercise (3)

Home

accommodations

None (19)

Items kept within reach near bed (11)

Exercise equipment (5)Rug placement (4)

Bathroom railings (4)

Emergency access button or necklace (1)

Wheelchair accessibility (1)

Exercise Walking (17)Yoga (3)

Swimming (5)

Biking (8)

Jogging/Running (3)

Aerobic exercise (3)

Page 23: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 23/34

Special Situations

Pregnancy

More severe (4) Less severe (6)Same

severity (7)

More frequent(7) Less frequent (4) Samefrequency (6)

Local

anesthesia

Did not trigger

attack (27)

Triggered attack

(4)

General

anesthesia

Did not trigger

attack (18)

Triggered attack

(9)

Page 24: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 24/34

Prevention: Diet

• Avoid foods rich in potassium

 – Fruits, fruit juices

• Avoid medications that elevate

potassium levels

 – Spironolactone, enalapril, valsartan

• Avoid fasting

• Some find that high salt intake reduces

attack frequency & severity

Page 25: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 25/34

Prevention: Activity

• Exercise

• Unclear how to advise

• Some individuals find that continuing mild exercise

after a period of more vigorous exercise can lessen anattack

• Avoid exposure to cold

Page 26: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 26/34

Prevention: Chronic Therapy

• Helpful medications:

 –  Thiazide diuretics

 –  Acetazolamide 

 –  Albuterol inhaler (1 to 2 puffs of 0.1 mg)

 –  Your physician should monitor your electrolyte

levels to ensure they remain in a safe range

Page 27: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 27/34

Management of Acute Attacks

• MILD - abort or prevent attacks at onset with:

 –  sugar

 –  mild exercise

• MODERATE/SEVERE – abort with: 

 –  thiazide diuretics (hydrochlorothiazide)

 –  inhaled beta adrenergic agonists (salbutamol)

 –  intravenously injected glucocorticoids?

 –  intravenous calcium gluconate [for heart]

Page 28: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 28/34

Hypotheses

• Treadmill at home: exercise but help will be

near

• Pace workout: use music for slow rhythm to

limit overexertion

• Meditation CD: prevent a stress-induced

attack when feeling overwhelmed or tense

• Tiger Balm or Advil: for post-attack muscle

stiffness and soreness

Page 29: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 29/34

Special Situations: Surgery

• Make anesthesia staff aware of diagnosis

• Opioids or depolarizing agents used in anesthesia myotonia

interfere with intubation / ventilation

• Breathing problems / weakness when recovering from general

anesthesia

 –  Prevent carbohydrate depletion – D5W is good!

 –  Avoid muscle relaxants

 –  Maintain a normal body temperature

 –  Keep serum potassium levels from being elevated

• Asymptomatic family members should be tested for the

family’s mutation before surgery so preventive measures can

be instituted

Page 30: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 30/34

Special Situations

• When you change routine, such as sleeping

late on holidays or weekends, attacks can

occur more frequently

 –  Wake up at your usual hour and have your regular

breakfast meal

• Albuterol is safe in pregnancy

Page 31: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 31/34

Tips from Fellow HyperPPers

• Know what works for you 

• Get all the support possible

Don't be afraid to talk about it• Stand up for your rights

• Learn all you can

•Diagnosis is a long road, but… 

• Get diagnosed!

Page 32: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 32/34

Tips from Fellow HyperPPers

• Know what works for you. My son & I both have pp but havedifferent severity and longevity.

• Get regular exercise, eat frequent small meals, reduce stress.

• Do not sit for longer period. Keep moving. Never skip food. Do notdo heavy exercise.

• Expect that most doctors you see are not going to believe you. But itis real, there are many people who have it and it can be managed.

• I spent many years being dismissed by various doctors for mysymptoms. It takes a long time to find someone who has heard ofthese conditions, and then figuring out how to manage them isanother long road .

• Get diagnosed

Page 33: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 33/34

Tips from Fellow HyperPPers

• Don't wait to find out as much as you can. I was misdiagnosed forover 40 years with hypo and it has now affected my health

• Get all the support possible , and don't be afraid to talk about it  ;stand up for your rights and don't put yourself in a situation youknow you will suffer in.

•Don't lie about it, explain to others what it is (which in mychildhood/teen years was impossible because no one knew what itwas). Join the PP list to share experiences with others and learn from them.

• Learn all you can! Talk with others, learn how to manage your diet.You can take control of many things, even though mid-attack you

have little to no control. When you're feeling strong - go out and dothings! Don't put things off, because you never know when the nextbig attack might come. We already must suffer being paralyzed physically, so let's not be paralyzed by fear, as well.

Page 34: 061111 HyperPP - PPA Presentation

7/23/2019 061111 HyperPP - PPA Presentation

http://slidepdf.com/reader/full/061111-hyperpp-ppa-presentation 34/34

Questions?

[email protected]